Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 9/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23150485 | 0.90 | MGLL (0.57) | MGLL | |
| SCHEMBL23850254 | 0.90 | MGLL (0.57) | MGLL | |
| SCHEMBL23150483 | 0.90 | MGLL (0.57) | MGLL | |
| SCHEMBL23181589 | 0.90 | MGLL (0.57) | MGLL | |
| SCHEMBL21730787 | 0.90 | MGLL (0.79) | MGLL | |
| SCHEMBL25785240 | 0.90 | MGLL (0.79) | MGLL | |
| SCHEMBL23852950 | 0.89 | MGLL (0.59) | MGLL | |
| SCHEMBL23853056 | 0.88 | MGLL (0.67) | MGLL | |
| SCHEMBL23852803 | 0.88 | MGLL (0.70) | MGLL | |
| SCHEMBL30775836 | 0.87 | MGLL (0.57) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883936-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-07-12 | — | — | EP | claimed |
| EP-3883936-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-09-29 | — | — | EP | claimed |
| US-12577257-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-3883936-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-07-12 | — | — | EP | disclosed |
| EP-3883936-B1 | NEW HETEROCYCLIC COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2023-07-12 | — | — | EP | disclosed |
| US-20210387999-A1 | HETEROCYCLIC COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2021-12-16 | — | — | US | disclosed |
| EP-3883936-A1 | NEW HETEROCYCLIC COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2021-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387999-A1 | HETEROCYCLIC COMPOUNDS | CYP1B1, CYP4B1, CYP4X1 | MGLL 1712/4885 |
| US-12577257-B2 | Heterocyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR1, CBR3 | MGLL 3086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.